BC Week In Review | Mar 8, 2019
Clinical News

Boehringer reports first data for IL-36R inhibitor in rare type of psoriasis

Boehringer said BI 655130 cleared symptoms of generalized pustular psoriasis within one week in a Phase I trial in seven patients experiencing an acute moderate-to-severe flare of the disease. BI 655130 is a mAb against...
Items per page:
1 - 1 of 1